Key facts
- Notable investors include NRL Capital, InnoPinnacle.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Jinling Biopharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Jinling Biopharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jinling Biopharmaceutical
Developer of biomedical solutions intended for scientific research and technical advancement. The company offers experimental development, technical consultation, technology transfer, and applied research services with a focus on areas excluding human stem cell and gene therapy applications, enabling the healthcare and life sciences market to access structured research capabilities while maintaining compliance with regulatory boundaries and fostering collaborative opportunities across academic and industrial sectors.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Jinling Biopharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jinling Biopharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jinling Biopharmaceutical in its N-PORT filings yet. We sweep new filings monthly.